USFDA classifies inspection at Cipla Kurkumbh facility as VAI
Mumbai: Cipla has informed in a BSE filing that the United States Food and Drug Administration (USFDA) has classified the routine current Good Manufacturing Practices (cGMP) inspection at the Company’s Kurkumbh manufacturing facility as Voluntary Action Indicated (“VAI”). VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory […]
